News Medical on MSN5d
Gene therapy breakthrough offers hope for severe Dravet syndrome cases
AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
A new gene therapy for children with Dravet syndrome developed
A team of researchers has developed a new gene therapy for children with Dravet syndrome - a rare type of epilepsy in ...
Pharm Exec2d
Biogen, Stoke Therapeutics Ink Deal to Develop Zorevunersen for Dravet Syndrome
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...
Science Daily6d
Gene therapy for rare epilepsy shows promise in mice
Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy.
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Discover Stoke Therapeutics' innovative RNA-based treatments like zorevunersen for Dravet syndrome, with a promising pipeline ...
technologynetworks5d
Epilepsy Gene Therapy Reduces Seizures and Prolongs Lifespan in Mice
Michigan Medicine researchers have developed a SCN1B gene therapy that restores brain function and survival in mice with ...
FierceBiotech5d
Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
BioSpace4d
Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...